X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The company will focus on developing first-in-class novel ketone-based therapies for chronic diseases of aging of which our first therapeutic focus is heart disease with secondary interests in neurological diseases.
Lead Product(s): Ketone-based Therapy
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: Selah Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 11, 2022
Details:
Proceeds will be used to fund LyGenesis’s Phase 2a clinical trial with a first patient in targeted for early 2021, also to push forward on their other cell therapies using lymph nodes as bioreactors to regrow functioning organs.
Lead Product(s): LYG-LIV0001
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: LYG-LIV0001
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Recipient: Lygenesis
Deal Size: $11.0 million Upfront Cash: Undisclosed
Deal Type: Financing December 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
